Safety review of combination drugs for hyperlipidemia

Expert Opinion on Drug Safety

Volumn 10, Issue 3, 2011, Pages 363-371

  Farnier, Michel ^a  

^a Point Medical   (France)

Author keywords

3 fatty acids; bile acid sequestrants; combination drugs; ezetimibe; fibrates; niacin; safety; statins; tolerability

Indexed keywords

BILE ACID SEQUESTRANT; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LAROPIPRANT PLUS NICOTINIC ACID; LOVASTATIN PLUS NICOTINIC ACID; MEVINOLIN; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; OMEGA 3 FATTY ACID; SIMVASTATIN;

BLEEDING; CHOLELITHIASIS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; LIVER DISEASE; MUSCLE DISEASE; MYALGIA; MYOPATHY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SKIN DISEASE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MUSCLES;

EID: 79955460186     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.540237     Document Type: Review

References (83)

1. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90 (Pubitemid 350137473)
2. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197
3. Grundy SM, Cleeman JI, Merz CNB, et al.; for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39 (Pubitemid 38924592)
4. Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28:2375-414
5. Waters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009;120:28-34
6. Barter P, Gotto AM, LaRosa JC, et al.; for the Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10 (Pubitemid 47481452)
7. Miller M, Cannon CP, Murphy SA, et al.; for the PROVE IT-TIMI 22 Investigators: impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008;51:724-30 (Pubitemid 351221217)
8. Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009;265:568-80
9. Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe : a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005;44:467-94 (Pubitemid 40733733)
10. Kashani A, Sallam T, Bheemreddy S, et al. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol 2008;101:1606-13
11. Davidson MH, Ballantyne CM, Kerzner B, et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004;58:746-55 (Pubitemid 39232318)
12. Davidson MH, Maccubbin D, Stepanavage M, et al. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006;97:223-8 (Pubitemid 43139240)
13. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial. JAMA 2004;292:1307-16 (Pubitemid 39223221)
14. The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy- a genomewide study. N Engl J Med 2008;359:789-99
15. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56
16. Baigent C, Landry M. Study of heart and renal protection (SHARP). Kidney Int 2003;63(Suppl 84):S207-10 (Pubitemid 36513411)
17. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/ simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-32
18. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008;359:1357-66
19. Alsheikh-Ali AA, Karas RH. Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: a post-marketing analysis. J Clin Lipidol 2009;3:138-42
20. Corsini A, Windler E, Farnier M. Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. Eur J Cardiovasc Prev Rehabil 2009;16:1-9
21. Fonseca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab 2010;15:384-92
22. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42
23. Kamanna VS, Vo A, Kashyap ML. Nicotinic acid: recent developments. Curr Opin Cardiol 2008;23:393-8 (Pubitemid 351787106)
24. Duggal JK, Singh M, Attri N, et al. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J Cardiovasc Pharmacol Ther 2010;15:158-66
25. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22
26. Alsheikh-Ali AA, Karas RH. The safety of niacin in the US Food and Drug Administration adverse event reporting database. Am J Cardiol 2008;101:9B-13B
27. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007;99:S22-31 (Pubitemid 46412228)
28. Perry CM. Extended-release niacin (nicotinic acid)/laropiprant. Drugs 2009;69:1665-79
29. Olsson AG. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease. Expert Opin Pharmacother 2010;11:1715-26
30. Bays HE, Ballantyne C. Whats the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol 2009;20:467-76
31. Alsheikh-Ali AA, Karas RH. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol 2007;99:379-81 (Pubitemid 46157217)
32. Sanford M. Curran MP. Niacin extended-release/Simvastatin. Drugs 2008;68:2373-86
33. Ballantyne CM, Davidson MH, McKenney J, et al. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I Study). Am J Cardiol 2008;101:1428-36
34. Karas RH, Kashyap ML, Knopp RH, et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia. The OCEANS Study. Am J Cardiovasc Drugs 2008;8:69-81 (Pubitemid 351570857)
35. McKenney J, Bays H, Koren M, et al. Safety of extended-release niacin/laropiprant in patients with dyslipidemia. J Clin Lipidol 2010;4:105-12
36. Shah S, Ceska R, Gil-Extremera B, et al. Efficacy and safety of extended-released niacin/laropiprant plus statin vs doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dislipidaemia. Int J Clin Pract 2010;64:727-38
37. FDA Drug safety communication: ongoing safety review of high-dose Zocor (simvatatin) and increased risk of muscle injury. Available from: http://www.fda. gov/Drugs/DrugsSafety/ PostmarketDrugSafety Informationforpatients [Accessed August 2010].
38. Health Sciences Authority. Available from: http://www.hsa.gov.sg/publish/ hsaportal/en/health-products-regulation/ safety-informations [Accessed August 2010]
39. Tredaptive: Laropiprant/nicotinic acid. Product information. Available from: http://www.ema.europa.eu/ema/index.jsp? curl=pages/medicines/human/ medicines [Accessed August 2010]
40. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553-64 (Pubitemid 36314342)
41. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol 2004;94:935-8 (Pubitemid 39349562)
42. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264:71-5 (Pubitemid 20209174)
43. Farnier M. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative. A critical review of potential benefits and drawbacks. Am J Cardiovasc Drugs 2003;3:169-78 (Pubitemid 36840975)
44. Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol 2009;5:507-18
45. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95:120-2 (Pubitemid 40051126)
46. Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Invest Drugs 2010;11:323-32
47. Corsini A, Bellosta S, Davidson MH. Pharmacokinetics interactions between statins and fibrates. Am J Cardiol 2005;96(suppl.):44K-49K
48. Franssen R, Vergeer M, Stroes ESG, Kastelein JJP. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab 2009;11:88-94
49. Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 2006;5:145-56 (Pubitemid 43056446)
50. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial). Am J Cardiol 2005;95:462-8 (Pubitemid 40247539)
51. Derosa G, Maffioli P, Salvadeo SAT, et al. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin 2009;25:1973-83
52. Farnier M, Ducobu J, Bryniarski L. Efficacy and safety of adding fenofibrate 160 mg in high risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg. Am J Cardiol 2010;106:787-92
53. Bays HE, Jones PH, Mohiuddin SM, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed hyperlipidemia. J Clin Lipidol 2008;2:426-35 (Pubitemid 352795715)
54. Roth EM, McKenney JM, Kelly MT, et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia. Am J Cardiovasc Drugs 2010;10:175-86
55. Kipnes MS, Roth EM, Rhyne JM, et al. Year two assessment of fenofibric acid and moderate-dose statin combination. A phase 3, open-label, extension study. Clin Drug Investig 2010;30:51-61
56. The ACCORD study group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
57. The ACCORD study group and ACCORD Eye study group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-44
58. Sacks FM, Carey VJ, Fruchart J-C. Correspondance to the Editor: Combination lipid therapy in type 2 diabetes. N Engl J Med 2010;363:692-3
59. Unal A, Torun E, Sipahioglu MH, et al. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients. Intern Med 2008;47:1017-9
60. Ireland JH, Eggert CH, Arendt CJ, Williams AW. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. Ann Intern Med 2005;142:949-50 (Pubitemid 40791815)
61. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol 2008;51:2375-84 (Pubitemid 351815163)
62. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007;99:3C-18C
63. Harris WS, Miller M, Tighe AP, et al. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008;197:12-24
64. Hoskins MH, Jacobson TA. Combination use of statins and omega-3 fatty acids: an emerging therapy for combined hyperlipidemia. Future Lipidol 2006;1:579-91
65. McKenney JM, Swearingen D, DiSpirito M, et al. Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. J Clin Pharmacol 2006;46:785-91 (Pubitemid 43882802)
66. Davidson MH, Stein EA, Bays HE, et al.; for the COMBination of prescription Omega-3 with simvastatin (COMBOS) investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:1354-67 (Pubitemid 47348116)
67. Maki KC, McKenney JM, Reeves MS, et al. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/d) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 2008;102:429-33
68. Yokoyama M, Origasa H, Matsuzaki M, et al.; for the Japan EPA lipid intervention study (JELIS) investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8 (Pubitemid 46483662)
69. Kosoglou T, Statkevich P, Fruchart J-C, et al. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin 2004;20:1197-207 (Pubitemid 39120784)
70. Farnier M, Freeman MW, Macdonell G, et al. for the ezetimibe study group. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005;26:897-905 (Pubitemid 40676570)
71. McKenney JM, Farnier M, Lo K-W, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006;47:1584-7
72. Jones MR, Baker BA, Mathew P. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet 2004;43:943-50 (Pubitemid 39447035)
73. McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin 2005;21:1403-12 (Pubitemid 41368572)
74. Insull W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. Southern Med J 2006;99:257-73
75. Xydakis Am, Guyton JR, Chiou P, et al. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol 2004;94:795-7 (Pubitemid 39221507)
76. Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther 2005;12:306-10 (Pubitemid 41391808)
77. Bays H, Rhyne J, Abby S, et al. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin 2006;22:2191-200 (Pubitemid 44789984)
78. Huijgen R, Abbink EJ, Bruckert E, et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther 2010;32:615-25
79. Guyton JR, Brown BG, Fazio S, et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol 2008;51:1564-72 (Pubitemid 351509420)
80. Fazio S, Guyton JR, Polis AB, et al. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am J Cardiol 2010;105:487-94
81. Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE. Available from: http:// www.clinicaltrials.gov/ct2/show/ NCT00461630?term=HPS2 +THRIVE&rank=1 [Accessed August 2010].
82. Farnier M, Roth E, Gil-Extremera B, et al.; for the ezetimibe/ simvastatin + fenofibrate study group. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J 2007;153:335.e1-335.e8
83. Polsani VR, Nambi V, Virani SS, et al. Efficacy and tolerability of multidrug therapy for hypertriglyceridemia. J Clin Lipidol 2009;3:341-4